Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…Huntington’s Disease Pathogenesis, Molecular Factors, and Potential for Combinatorial Therapies: A Focus on BDNF and NMDA Receptor Therapies
Objective: This paper outlines current therapeutic options for HD, and ultimately suggests taking a combinatorial therapeutic approach to slow HD progression by simultaneously treating multiple…Glunomab: a novel therapeutics for the treatment of Parkinson’s Disease
Objective: The focus of this study was: 1) to characterize the expression and the localization of an endogenous protease, tissue plasminogen activator (tPA) in the…Complex movement disorder presentations of autoimmune encephalitis – recovery at 4 weeks versus 4 years
Objective: The goal is to learn from different presentations of Autoimmune Encephalitis (AIE) so that we consider the diagnosis more quickly, pursue the work-up judiciously…24(S)-Hydroxycholesterol and cognition in Huntington’s disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)
Objective: To investigate correlations between plasma levels of 24(S)-Hydroxycholesterol (24[S]-HC) and cognitive performance in participants with Huntington’s disease (HD) using data from ENROLL-HD. Background: HD…GRIN2D is a cause of autosomal dominant form of Parkinson’s disease
Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…Isolated craniocervical dystonia without neuropsychiatric manifestations associated with NMDA-receptor antibodies
Objective: N-methyl-D-aspartate receptor (NMDAR) encephalitis classically spans neuropsychiatric disturbance, autonomic dysfunction and salient movement disorders. Attenuated presentations are increasingly recognised; however, presentations with an isolated…Movement disorders in pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis
Objective: Our aim was to investigate clinical characteristics and evolution of movement disorders (MD) in pediatric anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Background: Movement disorders account for…Combined anti N-Methyl-D- Aspartate receptor (NMDAR) encephalitis with autoimmune thyroiditis (AT), with good clinical recovery.
Objective: To report anti NMDAR encephalitis patient, with evidence of AT, and to explain her clinical presentation, management and outcome. Background: Autoimmune encephalitis(AE) is nowadays…NMDA Receptor Antibodies and Neuropsychiatric Symptoms in Parkinson’s Disease
Objective: To quantify the frequency of NMDA receptor (NMDAR) antibodies (Abs) in Parkinson’s disease (PD) and characterise their relationship with the cognitive and neuropsychiatric symptoms.…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.